This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
In this issue of Neurology®, Mendelson et al.1 use data from the Get With The Guidelines Stroke Registry to describe race- and gender-based disparities in IV alteplase (IV tissue plasminogen activator [tPA]), specifically the rates at which there is documentation that patients with acute ischemic stroke (AIS) decline treatment with thrombolytics. Among 177,115 patients (at >1,900 hospital sites) with AIS in whom no contraindications to tPA were documented, 3.7% were reported to have declined tPA. Compared with White individuals, the odds of tPA declination for Black patients were 21% higher (95% CI 1.11–1.31), while Asian patients had 28% lower odds of tPA declination (95% CI 0.48–0.88). Women were 17% more likely than men to have tPA declination documented (95% CI 1.11–1.23) as the reason for no tPA administration. Of note, the authors' statistical model included a large number of variables, including mode of and time to arrival, insurance status, medical comorbid conditions, the geographic location of the hospital, stroke center status, and other hospital characteristics such as annual stroke volume and percent of patients treated at the hospital site who were Black. Other variables that were significantly associated with an increased likelihood of tPA declination were older age (among those >65 years of age only) and having Medicaid insurance. Factors associated with a lower likelihood of tPA declination were treatment at a teaching hospital, larger annual IV tPA volume, and longer times from onset to arrival (but only among those arriving >90 minutes after symptom onset).
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the editorial.
See page 653
- © 2022 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
